STAA vs. RXST, EYE, WRBY, BLCO, GH, DYN, GERN, PRVA, NTLA, and AMN
Should you be buying STAAR Surgical stock or one of its competitors? The main competitors of STAAR Surgical include RxSight (RXST), National Vision (EYE), Warby Parker (WRBY), Bausch + Lomb (BLCO), Guardant Health (GH), Dyne Therapeutics (DYN), Geron (GERN), Privia Health Group (PRVA), Intellia Therapeutics (NTLA), and AMN Healthcare Services (AMN). These companies are all part of the "medical" sector.
STAAR Surgical (NASDAQ:STAA) and RxSight (NASDAQ:RXST) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
STAAR Surgical has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
STAAR Surgical currently has a consensus price target of $47.13, suggesting a potential upside of 13.04%. RxSight has a consensus price target of $60.63, suggesting a potential upside of 1.57%. Given STAAR Surgical's higher possible upside, research analysts plainly believe STAAR Surgical is more favorable than RxSight.
STAAR Surgical received 249 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 56.10% of users gave STAAR Surgical an outperform vote.
STAAR Surgical has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
In the previous week, RxSight had 17 more articles in the media than STAAR Surgical. MarketBeat recorded 39 mentions for RxSight and 22 mentions for STAAR Surgical. RxSight's average media sentiment score of 0.47 beat STAAR Surgical's score of 0.24 indicating that RxSight is being referred to more favorably in the news media.
STAAR Surgical has a net margin of 6.62% compared to RxSight's net margin of -54.57%. STAAR Surgical's return on equity of 8.73% beat RxSight's return on equity.
96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.0% of STAAR Surgical shares are owned by company insiders. Comparatively, 21.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
STAAR Surgical beats RxSight on 10 of the 18 factors compared between the two stocks.
Get STAAR Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
STAAR Surgical Competitors List
Related Companies and Tools
